STAMFORD, Conn., May 14 /PRNewswire/ -- Zargis Medical Corp., a
majority-owned subsidiary of Speedus Corp. (Nasdaq: SPDE), today
announced that its Zargis Cardioscan device and the compatible 3M™
Littmann® Electronic Stethoscope Model 3200 were the joint
recipients of a Gold Award on April
29th at The Edison Best New Products Award gala, presented
by Discovery Channel in New York
City. The prestigious Gold Award is the top honor given by
the Edison Award Steering Committee for product excellence in
innovation, creativity and ingenuity, as demonstrated by inventor
Thomas Alva Edison. Zargis and 3M
were recognized in the Electronics and Computers category—the
category in which the Apple® iPhone was the 2009 Gold Award
winner.
Zargis Cardioscan software supports physicians in analyzing
cardiac sounds for the identification and classification of
suspected murmurs, which can be signs of heart disease, and allows
healthcare professionals to record, visualize and transmit
recordings made with a stethoscope. The software represents a
breakthrough in computer-aided auscultation that has the potential
to reduce unnecessary referrals.
"Pairing the Littmann Electronic Stethoscope Model 3200 with
Zargis Cardioscan software is a huge advancement in changing the
way clinicians listen to and interpret heart sounds," said
Debra Rectenwald, president and
general manager, 3M Infection Prevention Division.
About Zargis Medical Corp.
Zargis is a global medical device company focused on improving
health outcomes and cost-effectiveness through diagnostic support
software and innovation. Zargis is majority-owned by Speedus
Corp. (Nasdaq: SPDE), and both 3M Company and Siemens Corporate
Research, a division of Siemens AG (NYSE: SI), hold equity
positions.
For additional information about Zargis or Speedus Corp.,
contact Peter Hodge at 888.773.3669
(ext. 23) or phodge@zargis.com, or visit the following Web sites:
www.zargis.com and www.speedus.com.
Statements contained herein that are not historical facts,
including but not limited to statements about the Company's
product, corporate identity and focus, may be forward-looking
statements that are subject to a variety of risks and
uncertainties. There are a number of important factors that could
cause actual results to differ materially from those expressed in
any forward-looking statements made by the Company, including, but
not limited to, the continuing development of the Company's sales,
marketing and support efforts.
SOURCE Speedus Corp.